PlainRecalls
FDA Drug Moderate Class II Terminated

VELCADE (bortezomib) for injection, 3.5 mg/vial, Reconstitution Information, SUBCUTANEOUS INJECTION ONLY add 1.4 mL 0.9% Sodium Chloride to make 2.5 mg/ mL final concentration, INTRAVENOUS INJECTION ONLY add 3.5 mL Sodium Chloride to 1 mg/mL final concentration, Rx Only, Distributed by MILLENNIUM Pharmaceuticals, Inc., Cambridge, MA 02139-4234, NDC 63020-0049-01

Reported: February 14, 2018 Initiated: January 30, 2018 #D-0425-2018

Product Description

VELCADE (bortezomib) for injection, 3.5 mg/vial, Reconstitution Information, SUBCUTANEOUS INJECTION ONLY add 1.4 mL 0.9% Sodium Chloride to make 2.5 mg/ mL final concentration, INTRAVENOUS INJECTION ONLY add 3.5 mL Sodium Chloride to 1 mg/mL final concentration, Rx Only, Distributed by MILLENNIUM Pharmaceuticals, Inc., Cambridge, MA 02139-4234, NDC 63020-0049-01

Reason for Recall

Defective Container: Confirmed reports of loose vial crimps.

Details

Units Affected
154,372 vials
Distribution
Distributed nationwide. They estimate 4% of the product may be recovered.
Location
Cambridge, MA

Frequently Asked Questions

What product was recalled?
VELCADE (bortezomib) for injection, 3.5 mg/vial, Reconstitution Information, SUBCUTANEOUS INJECTION ONLY add 1.4 mL 0.9% Sodium Chloride to make 2.5 mg/ mL final concentration, INTRAVENOUS INJECTION ONLY add 3.5 mL Sodium Chloride to 1 mg/mL final concentration, Rx Only, Distributed by MILLENNIUM Pharmaceuticals, Inc., Cambridge, MA 02139-4234, NDC 63020-0049-01. Recalled by Millennium Pharmaceuticals Inc.. Units affected: 154,372 vials.
Why was this product recalled?
Defective Container: Confirmed reports of loose vial crimps.
Which agency issued this recall?
This recall was issued by the FDA Drug on February 14, 2018. Severity: Moderate. Recall number: D-0425-2018.